目的 研究丁苯酞軟膠囊聯(lián)合注射用尤瑞克林治療急性腦梗死患者的臨床療效。方法 選取2014年4月-2015年3月天津市環(huán)湖醫(yī)院收治的急性腦梗死患者150例,根據(jù)抽取法將所有患者分為對(duì)照組和治療組,每組各75例。對(duì)照組靜脈滴注注射用尤瑞克林,0.15PNA加入生理鹽水250mL中,30min內(nèi)滴完,1次/d。治療組在對(duì)照組治療基礎(chǔ)上口服丁苯酞軟膠囊,0.2g/次,4次/d。兩組患者均連續(xù)治療14d。觀察兩組患者在治療前后血管內(nèi)皮功能指標(biāo)、日常生活能力(ADL)評(píng)分和神經(jīng)功能評(píng)分情況,同時(shí)比較兩組患者的臨床療效和在治療過(guò)程中的不良反應(yīng)發(fā)生率。結(jié)果 治療后,兩組患者的血漿內(nèi)皮素-1水平明顯降低,血漿一氧化氮水平顯著升高,同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度均優(yōu)于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組患者的ADL評(píng)分顯著升高,神經(jīng)功能評(píng)分明顯降低,同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度均優(yōu)于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,對(duì)照組和治療組的總有效率分別為74.67%、90.67%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療組和對(duì)照組的不良反應(yīng)率分別為4.00%、2.67%,組間比較差異不明顯。結(jié)論 丁苯酞軟膠囊聯(lián)合注射用尤瑞克林治療急性腦梗死的臨床療效較好,能夠明顯改善血管內(nèi)皮功能、日常生活能力和神經(jīng)功能,不良反應(yīng)率低,安全性高,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To study the effect of Butylphthalide Soft Capsules combined with Urinary Kallidinogenase for injection in treatment of acute cerebral infarction. Methods Patients (150 cases) with acute cerebral infarction in Tianjin Huanhu Hospital from April 2014 to March 2014 were randomly divided into control and treatment groups according to the extraction method, and each group had 75 cases. Patients in the control group were iv administered with Urinary Kallidinogenase for injection, 0.15 PNA added into 250 mL normal saline, finished during 30 min, once daily. The patients in treatment group were po administered with Butylphthalide Soft Capsules on the basis of the control group, 0.2 g/time, four times daily. The patients in two groups were treated for 14 d. After treatment, endothelial function index, ability of daily life (ADL) score, and nerve function score in two groups were observed, and efficacy and the incidence of adverse reactions in two groups during the process of treatment was evaluated. Results After treatment, levels of plasma endothelin-1 in two groups were significantly decreased, but levels of plasma nitric oxide in two groups were obviously increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, ADL scores in two groups were significantly increased, but nerve function scores in two groups were obviously decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant differenc between two groups (P < 0.05). After treatment, the efficacies in the control and treatment groups were 74.67% and 90.67%, respectively, and there were differences between two groups (P < 0.05). Adverse reaction rates of the treatment group and the control group were 4.00% and 2.67%, respectively, but there was no difference between two groups. Conclusion Butylphthalide Soft Capsules combined with Urinary Kallidinogenase for injection has clinical curative effect in treatment of acute cerebral infarction, can significantly improve endothelial function, ability of daily life, and nerve function, and has less adverse reactions, which has a certain clinical application value.